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Tuberculosis (TB) is an infectious disease caused by the bacillus 
Mycobacterium tuberculosis. It remains a major global health challenge 
and is the leading cause of death related to infection worldwide, 
exceeding HIV/AIDS.[1]
South Africa (SA) is among the top 20 high-burden countries 
in the world regarding TB, TB/HIV co-infection and multidrug-
resistant TB (MDR-TB).[1] Worldwide, ~10.4 million new cases of TB 
were diagnosed in 2016. Mortality remains high, with ~1.3 million 
TB deaths globally in 2016, and an additional 0.37 million deaths 
resulting from TB disease among HIV-positive individuals.[1]
Drug-resistant TB (DR-TB) threatens global TB control measures. 
A total of 490 000 new cases of MDR-TB were reported in 2016. 
MDR-TB is defined as TB strains with resistance to both isoniazid 
(INH) and rifampicin.[1,2] Trends among high-burden countries 
indicate an increase in MDR-TB cases, with the burden of MDR-TB 
increasing faster or decreasing slower than the overall TB burden.[1] SA 
had ~19 000 MDR-TB cases in 2016. SA also has one of the highest 
treatment failure rates among the 30 countries with a high burden 
of MDR-TB, with only 54% treatment success among patients with 
MDR-TB and rifampicin-resistant TB (RR-TB) in 2014.[1]
Various treatment strategies for the management of MDR-TB are 
available. The National Department of Health (NDoH) guideline 
for the management of DR-TB in SA was updated in 2013 and 
recommends a standardised approach for the management of MDR-
TB.[3] A standardised treatment approach relies on the knowledge of 
country-specific drug-resistance profiles and the frequency with which 
common second-line agents have been used as part of a programmatic 
approach in a specific geographical area.[2,3] A programmatic approach is 
ideally suited to settings where reliable individual drug-susceptibility 
testing (DST) is not readily available.[2] In SA, the recommended 
standardised regimen is an intensive phase consisting of 5 different 
drugs for 6 months. These agents are an injectable aminoglycoside 
(kanamycin or amikacin), moxifloxacin, ethionamide, terizidone and 
pyrazinamide (PZA). The aminoglycoside is then discontinued and a 
continuation phase comprising the remaining 4 drugs for 18 months 
is recommended.[3] In 2016, the World Health Organization (WHO) 
issued guidelines on the new shorter MDR-TB drug regimen lasting 
˂12 months. This standardised regimen consists of a 4 - 6 months’ 
intensive phase with kanamycin, moxifloxacin, prothionamide, 
clofazimine, PZA, high-dose INH and ethambutol. The continuation 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
Prevalence of isoniazid resistance-conferring 
mutations associated with multidrug-resistant 
tuberculosis in Free State Province, South Africa
L Pitso,1 MB ChB, MMed (Internal Medicine); S Potgieter,2 MB ChB, MMed (Internal Medicine); A van der Spoel van Dijk,3 MSc
1 Department of Internal Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa
2 Division of Infectious Diseases, Department of Internal Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa
3  Department of Medical Microbiology, Faculty of Health Sciences, University of the Free State and National Health Laboratory Service, Bloemfontein, 
South Africa
Corresponding author: L Pitso (pitsol@ufs.ac.za)
Background. Multidrug- and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB) threaten local and global control of the disease. 
The molecular line-probe assay (LPA) provides rapid diagnosis and early management of MDR-TB. The LPA detects mutations of katG and 
inhA genes associated with isoniazid (INH) resistance in Mycobacterium tuberculosis isolates. The katG and inhA genes are associated with 
high- and low-level INH resistance, respectively, as well as cross-resistance to ethionamide in the case of inhA gene mutations. Patients with 
MDR-TB due to an inhA mutation could benefit from the use of high-dose INH – instead of ethionamide – in their MDR-TB regimen.
Objectives. To determine the frequencies of katG and inhA mutations that conferred INH resistance among MDR-TB isolates during 
2014 - 2016 in Free State (FS) Province of South Africa.
Methods. We retrospectively reviewed MDR-TB isolates assayed with GenoType MTBDRplus (Hain Lifescience, Germany) (LPA) at the 
central TB laboratory of Universitas Academic Hospital, Bloemfontein, FS, and calculated the frequencies of katG and inhA mutations. 
Results. Among 918 MDR-TB isolates, the prevalence of katG, inhA and katG plus inhA mutations was 63.9%, 13.4% and 22.7%, respectively. 
Approximately 60% (n=536; 58.4%) of the isolates were obtained from male patients. The patients’ ages ranged from 1 to 89 (median 37) years. 
The Xhariep district had the highest incidence of INH resistance-conferring mutations in the province.
Conclusions. katG-associated mutations are the predominant INH resistance-conferring mechanism among MDR-TB isolates in the 
FS. Patients infected with isolates that harbour the katG mutation are unlikely to benefit from high-dose INH therapy in the bedaquiline 
(BDQ)-containing modified short MDR-TB regimen. They may, however, benefit from the inclusion of ethionamide in the regimen. 
Dual katG and inhA gene mutations make these patients unlikely to respond to either high-dose INH or ethionamide and should now be 
considered for either the BDQ-containing long MDR-TB regimen or an individualised treatment regimen, depending on fluoroquinolone 
susceptibility. Clinicians should familiarise themselves with interpreting various INH resistance-conferring mutation results and their 
implications for management of MDR-TB treatment. 
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phase comprises an additional 5 months, consisting of moxifloxacin, 
clofazimine, PZA and ethambutol.[4]
With recent advances in TB diagnostics, molecular testing 
provides rapid diagnosis and early management of DR-TB. The 
first-line molecular line-probe assay (LPA) GenoType MTBDRplus 
(Hain Life science, Germany) allows for rapid detection of resistance 
to rifampicin and INH.[1,2,5] This LPA is based on the extraction and 
amplification via multiplex polymerase chain reaction (PCR), and 
subsequent detection of M. tuberculosis DNA on a membrane strip 
using reverse hybridisation.[5] It facilitates the detection of the most 
common mutations in the rpoB gene associated with rifampicin 
resistance, high-level INH resistance due to mutations in the katG 
gene and low-level INH resistance due to inhA gene mutations.[2,5] 
LPA was endorsed by the WHO in 2008 for use on smear-positive 
sputum specimens and clinical isolates of M. tuberculosis grown on 
conventional cultures.[1,2] In 2011, the GenoType MTBDRplus version 2 
assay was validated for use in both smear-positive and smear-negative 
sputum samples.[6,7] The first-line LPA has a laboratory turnaround 
time of ~5 hours, allowing for both rapid diagnosis of MDR-TB and 
early initiation of treatment.[5,8] This test is now readily available in 
the SA public sector through the National Health Laboratory Service 
(NHLS).
Mutations resulting in rifampicin resistance are typically 
located in an 81 base-pair region within the rpoB gene, usually 
referred to as the rifampicin-resistance determining region (RRDR). 
More than 95% of mutations associated with rifampicin resis-
tance occur in this region.[2,9] Although INH resistance is associated 
with resistance-conferring mutations in multiple genes, katG 
and inhA account for ~90% of resistance detected by phenotypic 
DST.[9,10]
INH was first reported to be an effective antituberculosis drug in 
1952.[11] Mutations conferring INH resistance have since emerged 
and are associated with deletions of the catalase-peroxidase gene 
(katG), and/or mutations in the inhA gene responsible for mycolic 
acid synthesis. The katG mutations are associated with high-level 
INH resistance and inhA mutations with low-level resistance.[11] In 
the presence of inhA mutations, significant cross-resistance between 
INH and ethionamide has been observed.[2,9] Prior to the widespread 
use of first-line LPA and routine reporting of specific INH resistance-
conferring mutations, ethionamide was considered to be one of the 
active drugs used as part of standardised MDR-TB treatment in 
SA.[3] However, use of ethionamide in the presence of a known inhA 
mutation is regarded as ineffective. In this setting, its use could not 
only cause unwanted adverse effects without clear benefit to the 
patient, but could contribute to the development of further resistance 
by exposing the patient to an inadequate regimen.[5] There is evidence, 
however, to support the use of high-dose INH in patients with MDR-
TB with a known inhA mutation.[2,12] Use of LPA has made it possible 
to rapidly diagnose MDR-TB and provide information regarding 
the common mutations conferring resistance to both rifampicin 
and INH. The mutation type associated with INH resistance was 
not routinely reported by the TB laboratory in the FS until late 
2015. Therefore, this information was not previously available to the 
attending clinician.
The contribution of katG, inhA and katG plus inhA mutations in 
the setting of MDR-TB is not known in the FS. The aim of this study 
was to retrospectively determine the prevalence of katG, inhA and 
katG plus inhA genetic mutations associated with INH resistance 
in patients from the FS with MDR-TB identified by LPA during 
2014 - 2016.
Methods
Setting
In the FS, first-line TB LPA tests are referred to a central TB 
laboratory at Universitas Academic Hospital, Bloemfontein. The 
province has a population of ~2.7 million.[13] It has the fifth highest 
incidence of TB in SA, with 575 cases per 100 000 population.[14] 
The province had 267 laboratory-confirmed MDR-TB cases in 2010, 
representing 3.6% of the national burden.[3] All 5 provincial districts 
and their respective municipalities refer samples to the central TB 
laboratory for first-line LPA testing when appropriate, as indicated 
on a map of the FS showing the different districts and municipalities 
(Fig. 1).[13,15] On average, the laboratory annually performs 2 300 first -
line LPA tests.
Data collection
Data of all LPA tests (N=6 648) performed from January 2014 
to December 2016 were reviewed retrospectively. Smear-positive 
clinical samples and/or culture-positive isolates across all age and 
gender groups were included in the final analysis if M. tuberculosis 
complex was detected and resistance to both rifampicin and INH 
was confirmed. The performance of LPA on smear-negative samples 
was not validated at the time; these results were excluded from the 
analysis.
Data were retrieved from LPA reports retained on site at the central 
TB laboratory in the FS, as well as the corporate data warehouse at 
the NHLS head office in Johannesburg. The NHLS corporate data 
warehouse stores laboratory tests and demographic details for all 
patients receiving healthcare in the public sector, amounting to ~80% 
of the total SA population. Data were screened for duplication, and 
where multiple isolates from one patient were encountered, only 
the first sample was used. Data were sorted according to the type of 
mutation (katG, inhA or both), age, gender and district municipality. 
Analysis
All data were entered into a Microsoft Excel (Microsoft, USA) 
workbook for analysis. Descriptive statistics, i.e. frequencies and 
percentages for categorical data, were calculated. The prevalence 
 
Fig. 1. Map of Free State Province showing one metro (Mangaung), four districts 
and their municipalities. The numbers represent the population per 
district.
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of katG, inhA and a combination of the 
two mutations was calculated for the total 
samples per year and per district, and 
described by means of 95% confidence 
intervals (CIs). Population data were used to 
calculate prevalence per 100 000 population.
Ethical approval
This study was approved by the Ethics 
Committee of the Faculty of Health 
Sciences, University of the Free State (ref. 
no. ECUFS 223/2015). Informed consent 
was not deemed necessary by the committee, as 
the data included in the study were collected 
previously during clinical care, and confi-
dential data were accessed only by autho-
rised personnel conducting the study, who 
signed a confidentiality agreement with the 
laboratory. To ascertain anonymity, personal 
information was excluded from the final 
analysis once data were sorted. 
Results
A total of 6 648 LPA test results were 
reviewed. Of these, 918 (13.8%) isolates 
fulfilled the inclusion criteria and were 
available for the final analysis. The results 
represented patients from the entire FS 
population from 2014 to 2016. The remaining 
5 730 data results were excluded from the 
study for several reasons (Fig. 2), including 
missing patient information, rifampicin or 
INH mono-resistance, non-tuberculosis 
myco bacteria, and data duplication due to 
more than one sample from a single patient 
sub mitted during the study period.
The median age of patients whose test 
results were recorded was 37 (range 1 - 89) 
years. More than half of the patients were 
male (n=536; 58.4%). As shown in Table 1, of 
the 918 test results included in the study, 587 
(63.9%) isolates had only katG mutations 
detected by LPA, 123 (13.4%) had only inhA 
mutations, and the remaining 208 (22.7%) 
had both katG and inhA mutations. Table 2 
summarises the total number of mutations 
for each year of the study period.
Table 3 shows that the highest number 
of samples included in the study (n=312; 
34.0%) was received from the Mangaung 
metropolitan municipality and the lowest 
number (n=63; 6.9%) from the Xhariep dis-
trict. The number of mutations relative to 
population size was 43/100 000 and 22/100 000 
in Xhariep and Fezile Dabi districts, respec-
tively (Table 3).
Discussion
We examined the local prevalence of the 
most common mutations of the inhA and 
katG genes associated with INH resistance 
among MDR-TB isolates. To our knowledge, 
this is the first study in the FS to report 
findings on this matter. 
The katG gene mutation, conferring high-
level INH resistance, was found in 63.9% 
of MDR-TB isolates tested, which was 
consistent with previous research identifying 
katG as the predominant gene associated 
with INH resistance in MDR-TB isolates. An 
Indian study showed that 94% of MDR-TB 
isolates had a katG mutation.[16] Barnard et al.[17] 
Excluded because of 
data duplication 
(n=604)
LPA reviewed 
(n=6 648)
Clinical information 
(n=6 646)
Valid LPA test results 
(n=6 561)
LPA with Mycobacterium 
tuberculosis complex 
(n=6 380)
Drug-resistant TB 
(n=3 004)
MDR-TB 
(n=1 522)
LPA with MDR-TB
 (n=918)
Excluded because of 
missing information 
(n=2)
Excluded because of
invalid test results 
(n=85)
Excluded because of 
non-tuberculosis 
mycobacteria (n=181)
Excluded because of 
drug-sensitive TB 
(n=3 376)
Excluded because of 
rifampicin/INH mono-resistance, 
or inconclusive (n=1 482)
Fig. 2. Diagrammatical summary of data collection and study criteria. (LPA = line-probe assay; 
TB = tuberculosis; INH = isoniazid; MDR = multidrug-resistant.)
Table 1. Frequency (n) and type of mutation in multidrug-resistant isolates of 
Mycobacterium tuberculosis (N=918)
Gene n (%) 95% CI (%)
katG only (high-level INH) 587 (63.9) 60.8 - 67.0
inhA only (low-level INH plus ethionamide resistance) 123 (13.4) 11.3 - 15.8
katG and inhA combined 208 (22.7) 20.1 - 25.5
CI = confidence interval; INH = isoniazid.
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reported a mutation in the katG gene in 64.1% of all INH-resistant 
strains in the public sector in Western Cape Province of SA, of which 
70.8% were MDR-TB strains.[17]
Our finding that 13.4% of MDR-TB isolates had an inhA gene 
mutation was comparable with results reported by Yadav et al.,[16] 
who documented an inhA gene mutation in 14% of MDR isolates. 
However, the study conducted in the Western Cape showed that 41.9% 
(38.2% of MDR-TB strains) had a mutation in the inhA gene.[17]
Dual inhA and katG mutations were observed among 22.7% of 
strains in our study, which were higher than those documented in 
both the Indian (6%)[16] and Western Cape (10.5%)[17] studies. It 
should be noted, however, that the Indian study investigated MDR 
isolates specifically,[16] while the Western Cape group included all 
INH-resistant isolates in their study.[17] In KwaZulu-Natal, a province 
with a high TB prevalence, 15% of MDR-TB isolates showed dual 
katG and inhA gene mutations.[18] Several other studies worldwide 
have shown similar results, but with considerable geographical 
variation.[9,19-22]
While katG is known to confer high-level resistance to INH with 
no documented cross-resistance, inhA gene mutations are associated 
with low-level INH resistance and cross-resistance to ethionamide.[2,9,11,23] 
Ethionamide was recommended in the 2013 NDoH guideline on 
DR-TB, and was included as part of the standardised treatment 
regimen for MDR-TB in the SA setting.[3] Consequently, it was 
commonly used in the management of all MDR-TB patients in the 
FS until the end of 2015, regardless of the type of INH resistance-
conferring mutation. Therefore, up to 36.1% of patients (those 
with TB strains harbouring an inhA gene mutation) might have 
been treated inadequately. The use of ethionamide in the presence 
of inhA mutations would not have been effective against MDR-
TB owing to this cross-resistance.[2] In the absence of the clear 
benefits of ethionamide, the risk of known adverse effects such 
as hypothyroidism, teratogenicity, nausea and vomiting may be 
unacceptably high in this instance. Furthermore, ethionamide is 
more expensive and not as widely available as INH.[12,24,25]
Katiyar et al.,[12] in a randomised study, showed that high-dose 
INH (16 - 18 mg/kg/day) benefit patients with MDR-TB. They found 
significant improvement in the time to sputum culture conversion 
and the likelihood of patients being sputum culture-negative at 6 months 
compared with placebo and normal-dose INH.[12] Victor et al.[25] also 
supported the use of high-dose INH, as their study demonstrated 
that ~50% of INH-resistant isolates had low minimal inhibitory 
concentrations (MICs) that could be overcome by using higher 
doses of INH.[25] Another prospective study of children ˂13 years 
old conducted in the Western Cape, found that >80% of INH mono-
resistant and MDR infections could be treated with high-dose INH 
(15 - 20 mg/kg/day).[26]
A katG mutation confers high-level INH resistance and an inhA 
mutation confers ethionamide cross-resistance.[2,9,11,23] Therefore, 
patients with dual inhA and katG mutations (22.7% in our study) 
are unlikely to respond to either high-dose INH or ethionamide, and 
therefore need to be considered for an individualised TB regimen.
The outcome of MDR-TB treatment has been notoriously poor 
using conventional 18 - 24-month regimens, with a success rate of 
54%.[1] Not only are these regimens lengthy, posing an adherence 
problem, but they involve the use of second-line drugs, which are not 
only less effective, but more expensive and have a worse side-effect 
profile than first-line drugs.[3] This has led to a search for shorter, 
more effective regimens. A number of trials have recently proven 
the effectiveness of a 9 - 12-month regimen.[27-30] In 2016, the WHO 
endorsed the use of an MDR-TB short course consisting of an initial 
phase of kanamycin, moxifloxacin, high-dose INH, ethionamide, 
clofazimine, PZA and ethambutol.[4,31] The original short-course 
MDR-TB regimen study was conducted in Bangladesh, India, in 
a setting where LPA for first-line drug-resistance testing was not 
performed; therefore, the INH resistance-conferring mutations were 
not known. Nevertheless, the treatment outcome was good.[32] In our 
study, 36.1% of patients had TB infection with strains demonstrating 
an inhA mutation, which would be expected to render resistance to 
ethionamide, one of the key drugs in the 2016 short-course regimen. 
While the Bangladesh cohort demonstrated a good outcome despite 
not knowing the specific INH-resistance mutation,[32] it is our opinion 
that taking into account its expense and considerable toxicity, we have 
to question the use of ethionamide in situations where resistance 
is clearly known. Since release of the WHO recommendations of 
2016,[4,31,33] the NDoH has started implementing this short regimen 
in qualifying patients, unless their isolates demonstrate dual katG 
and inhA mutations that exclude them from the regimen.[34] In our 
setting, this will expose the 13.4% of patients with only an inhA 
mutation to unnecessary adverse effects of ethionamide. 
In the latter part of 2018, the WHO released a rapid communication 
report further modifying the treatment of MDR-TB to a bedaquiline 
(BDQ)-containing, injectable-free regimen.[35] BDQ is one of only 
two new approved TB drugs (delamanid (DLM) being the second) 
that have been developed in the past 50 years to treat TB.[36] 
In response, the NDoH has released interim guidelines on the 
implementation of new injectable-free regimens in SA.[37] However, 
most SA patients still receive the previous long regimen of at least 
18 months’ duration, and some the short regimen that includes both 
ethionamide and high-dose INH.[37] 
With the new injectable-free short regimen that includes the use of 
BDQ, high-dose INH is retained while ethionamide is removed from 
the regimen, irrespective of katG or inhA mutation.[37] Patients in our 
study whose isolates showed inhA mutations (13.4%), would benefit 
from this modified short regimen. 
However, although the modified short regimen appears to be 
promising, the 63.9% of isolates that showed high-level resistance 
due to katG mutations would theoretically be expected to benefit 
from ethionamide instead of high-dose INH. In our view, it would 
Table 3. Frequency (n) of isoniazid mutations* among multidrug-
resistant Mycobacterium tuberculosis isolates (N=918) by district
District municipality n (%)
Total per 100 000 
population, n
Fezile Dabi 108 (11.8) 22
Lejweleputswa 259 (28.2) 41
Mangaung metro 312 (34.0) 42
Thabo Mofutsanyana 176 (19.2) 24
Xhariep 63 (6.9) 43
*Isoniazid mutations include isolates with either katG, inhA or both katG and inhA. 
Table 2. Mutation frequency (n) among multidrug-resistant 
Mycobacterium tuberculosis isolates by year
Year
Mutation
inhA, n (%) katG, n (%)
inhA and kat G, 
n (%)
2014 (n=347) 42 (12.1) 213 (61.4) 92 (26.5)
2015 (n=267) 37 (13.9) 167 (62.6) 63 (23.6)
2016 (n=304) 44 (14.5) 207 (68.1) 53 (17.4)
Total (N=918) 123 (13.4) 587 (63.9) 208 (22.7)
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be worth following up the group of patients with high-dose INH 
included in their regimen, despite the known high-level resistance 
to INH due to a katG mutation, to determine if treatment outcomes 
were replicated. The remaining 22.7% of isolates with dual katG 
and inhA mutations would not be suitable for this modified short 
regimen and are recommended for the new long regimen, provided 
that fluoroquinolone sensitivity is confirmed.[37] In contrast to the 
short modified regimen where high-dose INH is used, irrespective 
of the presence of either katG or inhA alone, the guideline offers a 
different recommendation in the long regimen. In the latter regimen, 
either ethionamide (only katG) or high-dose INH (only inhA) may 
be used, but neither if both mutations are present. This is particularly 
important where access to new drugs such as BDQ and DLM is 
uncertain, in children ˂12 years of age due to safety concerns, or 
shortage of supply.[37]
Our study did not investigate the relationship between INH 
resistance-conferring mutations and history of prior use of INH. 
Bollela et al.[38] reported a direct link between prior INH exposure 
for latent or active TB and predominance of katG mutations. They 
found that a katG mutation was more frequent among isolates 
from patients with a history of INH use than in those with no 
INH exposure (68.8% v. 31.2%). However, this finding did not 
represent a statistically significant difference.[38] This subject remains 
unanswered by our study and could be an area for further research.
We also found a comparatively higher number of INH resistance-
conferring mutations per population size in the Xhariep district. 
Although it is geographically the largest of the 5 districts in the 
province, it is also the least densely populated.[13,15,39] We found that 
the incidence of INH resistance-causing mutations was 43/100 000 popu -
lation in the Xhariep district (Table 3), which was the highest in the 
province. Several factors could explain this finding. The Xhariep 
district had the highest TB incidence rate of any district in the FS in 
2015 at 784/100 000 population, which was well above the national 
average of 520/100 000.[40] Furthermore, this finding was associated 
with the worst TB patient treatment success rate of 72.8%, which 
was below the provincial and national averages of 80.1% and 81%, 
respectively.[41] This implies that a proportion of patients did not 
complete the treatment for drug-sensitive TB or did not achieve cure. 
Both these factors would contribute to further development of drug 
resistance and continual spread among the uninfected population. 
Moreover, the loss-to-follow-up rate in 2014 among DR-TB patients 
was the second highest in the province (27.5%), close to 10% more 
than the national average of 17.9%.[41] Even though some of these 
patients might have been lost to follow-up due to death, those who 
stayed alive would have been treated inadequately, and therefore 
continue to infect the exposed population and to spread resistant 
strains. Client adherence to treatment is known to be negatively 
affected by alcohol abuse, unemployment and poor access to quality 
healthcare.[42] The Xhariep district has an unemployment rate of 
27%, with the age group 15 - 34 years having a particularly high 
rate of 33.8%.[13,41] Healthcare resources are also limited, with only 
88 professional nurses and 10 medical practitioners providing 
services in the area in 2016.[41]
Our study revealed that the Mangaung metro had the second highest 
incidence of INH resistance-conferring mutations (42/100 000 popu -
lation). It has the highest population of all the districts in the province 
and is one of the wealthiest economically.[40] The high incidence of 
INH resistance-associated mutations is possibly due to urbanisation 
and immigration of people from other districts seeking employment 
and better health services. Lejweleputswa – a prominent mining industry 
district[39] – had the third highest incidence (41/100 000) of mutations 
associated with INH resistance. Despite having a population 
smaller than Thabo Mofutsanyana (a former homeland and largely 
agricultural district),[13,39] Lejweleputswa district in our study had 
nearly double the incidence of INH resistance-conferring mutations 
than that observed in Thabo Mofutsanayana. This is most likely due 
to mining and its association with a high incidence of TB due to 
silica dust exposure among mineworkers that impairs macrophage 
function, leading to a predisposition to TB.[42]
Study limitations
Certain limitations to our study need to be noted. The retrospective 
design might have introduced selection or information bias. We 
also did not have comparative phenotypic DST to correlate the 
performance and agreement between genotypic and phenotypic 
DST with regard to the diagnosis of MDR-TB in our setting. 
However, performance of genotypic/molecular DST has been shown 
to be comparable with that of phenotypic DST and is unlikely to be 
a major factor.[16,17,43-45] We did not analyse second-line resistance 
and some of these isolates might have demonstrated resistance to 
second-line drugs, which would render them XDR-TB rather than 
MDR-TB isolates. Further research in this regard is recommended.
Conclusions
We investigated the prevalence of INH resistance-conferring mutations 
in the FS and found that at least 13.4% of MDR-TB isolates have an 
inhA mutation as tested by LPA. Up to 22.7% of isolates have dual 
inhA and katG gene mutations. The use of ethionamide as part of an 
MDR-TB regimen in both these groups of patients probably represents 
an inadequate treatment regimen, with the resultant risk of treatment 
failure and development of further drug resistance. It also exposes the 
patient to unnecessary drug toxicity. Likewise, the 63.9% of patients 
infected with MDR-TB strains exhibiting high-level INH resistance due 
to the katG mutation, are unlikely to benefit from high-dose INH in the 
BDQ-containing modified MDR-TB short regimen and may benefit 
from the use of ethionamide. As these mutations are now routinely 
reported by the TB laboratory in the FS, it is of vital importance 
that clinicians know how to interpret the results and are aware of 
the treatment implications of TB associated with the various INH 
resistance-conferring mutations. This knowledge of genetic mutations 
associated with INH resistance and effective implementation of new 
regimens could help to improve the effectiveness of MDR-TB treatment 
and thus improve morbidity and reduce further transmission. This 
needs careful consideration, as new guidelines for the management of 
MDR-TB are being formulated in SA.
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